PASG Company Profile and Key Details

Q: Who are the executives of PASG?

Ms. Simona KingChief Financial Officer & Corporation Sec.David Weinstein M.D.Senior Vice President of Clinical Devel.Dr. William Chou M.D.Pres, Chief Executive Officer & DirectorMr. Edgar B. Cale Esq., J.D.Gen. Counsel & Company Sec.Gregory FuestVice President of Global Commercial Strategy & MarketingDr. Mark Forman M.D., Ph.D.Chief Medical OfficerDr. James M. Wilson M.D., Ph.D.Co-Founder & Chief Scientific AdvisorMr. Alexandros Fotopoulos MBA, MScChief Technical OfficerMr. Stuart M. HendersonSenior Vice President of Corporation Devel. & Investor RelationsDesiree Luthman D.D.S.Senior Vice President of Global Regulatory AffairsDr. Desiree Luthman D.D.S.Senior Vice President of Global Regulatory AffairsMs. Kathleen BorthwickSenior Vice President of Fin., Principal Accounting Officer & Interim Chief Financial OfficerEden FucciSenior Vice President of Technical Operations

NASDAQ : PASG

Passage Bio

$4.57

-0.05-1.08%

At Close 4:00 PM

$4.50

−0.32-6.64%

After-Market 05:00 PM

60.3

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Passage Bio, Inc. (PASG) stock declined over -1.08%, trading at $4.57 on NASDAQ, down from the previous close of $4.62. The stock opened at $4.53, fluctuating between $4.42 and $4.57 in the recent session.

Stock Snapshot

4.62

Prev. Close

14.68M

Market Cap

4.42

Day Low

-0.39

P/E Ratio

-11.84

EPS (TTM)

-1.43

Cash Flow per Share

4.53

Open

3.21M

Number of Shares

4.57

Day High

90.2%

Free Float in %

2.03

Book Value

13.41K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 28, 2026	4.53	4.57	4.42	4.57	13.41K
Jul 27, 2026	4.85	4.95	4.55	4.62	29.52K
Jul 24, 2026	4.79	5.00	4.60	4.94	95.41K
Jul 23, 2026	4.82	4.90	4.82	4.90	2.12K
Jul 22, 2026	4.74	5.00	4.68	4.92	34.02K
Jul 21, 2026	4.80	4.91	4.79	4.91	9.92K
Jul 20, 2026	4.83	5.00	4.75	4.81	80.7K
Jul 17, 2026	4.90	4.91	4.68	4.83	55.43K
Jul 16, 2026	4.94	5.01	4.88	4.91	76.04K
Jul 15, 2026	4.42	5.00	4.42	4.91	57.78K
Jul 14, 2026	4.37	4.64	4.25	4.44	58.8K
Jul 13, 2026	4.62	4.74	4.31	4.46	94.94K
Jul 10, 2026	4.66	4.66	4.42	4.57	39.6K
Jul 09, 2026	4.75	4.78	4.59	4.71	19.44K
Jul 08, 2026	4.92	4.92	4.59	4.82	26.32K
Jul 07, 2026	4.67	5.06	4.60	5.00	68.26K
Jul 06, 2026	4.48	4.78	4.48	4.70	19.87K
Jul 02, 2026	4.64	4.73	4.45	4.68	44.64K
Jul 01, 2026	4.92	4.92	4.42	4.58	57.74K
Jun 30, 2026	4.90	4.99	4.76	4.88	89.29K

Contact Details

Philadelphia, PA 19103

United States

https://www.passagebio.com 267 866 0311

About Company

Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.

Stock Peers

ARGX

-16.59-1.87%

argenx SE$872.23 REGN

28.01+4.20%

Regeneron Pharmaceuticals, Inc.$695.18 MDGL

-12.45-2.26%

Madrigal Pharmaceuticals, Inc.$538.80 UTHR

-4.31-0.82%

United Therapeutics Corporation$523.63 VRTX

11.39+2.38%

Vertex Pharmaceuticals Incorporated$490.39 KRYS

12.41+3.53%

Krystal Biotech, Inc.$364.23 ONC

4.56+1.40%

BeOne Medicines AG$330.46 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-1.22-0.41%

Ligand Pharmaceuticals Incorporated$296.28 PRAX

-19.99-6.33%

Praxis Precision Medicines, Inc.$295.81

Company Overview

Passage Bio, Inc. (NASDAQ:PASG) closed at $4.57 USD, losing -$0.05 (-1.08%) from the previous close of $4.62. The stock is currently mid-range between its 52-week high and low $3.29 and $20.00. With a market capitalization of about $14.68 million, Passage Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.42). Key stats such as the average daily volume over the past year has been around 87.37 thousand shares, volume is running light vs its 52-week average. Headquartered in Philadelphia, PA, Passage Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO William Chou, the company employs approximately 24 people and listed since February 28, 2020. Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -9.07%, SMA50 -24.97%, SMA200 1.31%). The stock’s 14-day RSI is 38.74 (weak momentum), while the ATR of 1.18 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -56.7% below its high and over 69.01% above its low. Average 10-day trading volume of 37.87 thousand shares is below the 3-month average of 86.72 thousand, indicating normal recent market interest.

Valuation Metrics

Passage Bio, Inc. trades at a P/E ratio of -0.38, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.23 suggesting the stock is closer to book value. The P/FCF stands at -0.47, also above market averages.

Dividend & Fair Value

Passage Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $7.03. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Passage Bio, Inc. generated EPS of -$14.46 over the past year. Five-year average earnings growth is -1.48%. Wall Street analysts project EPS growth of 50.89% annually over the next five years. The latest quarter delivered EPS of -$2.36. The next quarter is forecast at -$2.57. Next year's EPS is expected at $30.65. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 4 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $67.00 to $7.00. The high target offers 1366.08% upside. The low target suggests 53.17% downside. The mean target is $29.44. This offers 544.2% upside. Passage Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 9.77%. The prior quarter beat by 86.3%. Over the last six quarters, Apple has recorded several small beats. These include -4.76% in March 04, 2025.

Shareholding & Insider Activity

Passage Bio, Inc. has 3.21 million shares outstanding. The public float is 2.89 million shares, elevated short interest at 4.84% of float. This equals 124.63 thousand shares. The short ratio is 0.83 days. Institutional investors hold 65.37% of the float. Insiders own 7.72%. OrbiMed Capital GP VII LLC holds 6.54 million shares, ORBIMED ADVISORS LLC has 6.07 million shares and Frazier Life Sciences IX, L.P. has 5.01 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Passage Bio has not generated any revenue. Returns are negative, with ROA at -67.80% and ROE at -91.71%.
On valuation metrics, Passage Bio trades at a P/E of -0.38, P/S of 0.00 and P/B of 1.23. The current ratio is 1.73 and quick ratio is 1.73. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1453.34 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.49, supported by a cash flow-to-debt ratio of -5.33.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Passage Bio posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $3.72M (margin 0.00%). Operating income was - $100.14M (margin 0.0%). Net income was- $102.06M (EPS - $1.86).
The company ended the quarter with $114.29M in cash and short-term investments, a total debt of $26.29M, and net debt of $4.59M. Total assets were $150.55M, with equity of $111.28M. Financials further reflected weakness, with operating cash flow of - $78.26M, free cash flow of - $78.41M, and capital expenditures of - $146.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Passage Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.84%, with price expected at $4.44 by August 10, 2026, within a range of $4.02 to $4.91 3-Month Outlook: Projected fall of -40.26%, reaching $2.73 by October 23, 2026, with a range of $2.27 to $3.19. 1-Year Outlook: Projected loss of -38.95%, with price at $2.79 by July 27, 2027, within a range of $0.00 to $0.47.

Key Takeaways

Passage Bio, Inc. (NASDAQ:PASG) shares are flat 8.22% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Passage Bio, Inc. trading at a premium to the broader market with a P/E of -0.38. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $21.13, suggesting 362.36% upside. Our AI forecast model points to short-term weakness (-2.84% over two weeks), a medium-term fall (-40.26% over three months), and a longer-term loss (-38.95% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Passage Bio, Inc. (PASG) stock price?

Passage Bio, Inc. (NASDAQ: PASG) stock price is $4.57 in the last trading session. During the trading session, PASG stock reached the peak price of $4.57 while $4.42 was the lowest point it dropped to. The percentage change in PASG stock occurred in the recent session was -1.08% while the dollar amount for the price change in PASG stock was - $0.05.

PASG's industry and sector of operation?

The NASDAQ listed PASG is part of Biotechnology industry that operates in the broader Healthcare sector. Passage Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PASG?

Ms. Simona King
Chief Financial Officer & Corporation Sec.
David Weinstein M.D.
Senior Vice President of Clinical Devel.
Dr. William Chou M.D.
Pres, Chief Executive Officer & Director
Mr. Edgar B. Cale Esq., J.D.
Gen. Counsel & Company Sec.
Gregory Fuest
Vice President of Global Commercial Strategy & Marketing
Dr. Mark Forman M.D., Ph.D.
Chief Medical Officer
Dr. James M. Wilson M.D., Ph.D.
Co-Founder & Chief Scientific Advisor
Mr. Alexandros Fotopoulos MBA, MSc
Chief Technical Officer
Mr. Stuart M. Henderson
Senior Vice President of Corporation Devel. & Investor Relations
Desiree Luthman D.D.S.
Senior Vice President of Global Regulatory Affairs
Dr. Desiree Luthman D.D.S.
Senior Vice President of Global Regulatory Affairs
Ms. Kathleen Borthwick
Senior Vice President of Fin., Principal Accounting Officer & Interim Chief Financial Officer
Eden Fucci
Senior Vice President of Technical Operations

How PASG did perform over past 52-week?

PASG's closing price is 38.91% higher than its 52-week low of $3.29 where as its distance from 52-week high of $20.00 is -77.15%.

How many employees does PASG have?

Number of PASG employees currently stands at 24.

Link for PASG official website?

Official Website of PASG is: https://www.passagebio.com

How do I contact PASG?

PASG could be contacted at phone 267 866 0311 and can also be accessed through its website. PASG operates from One Commerce Square, Philadelphia, PA 19103, United States.

How many shares of PASG are traded daily?

PASG stock volume for the day was 13.41K shares. The average number of PASG shares traded daily for last 3 months was 87.37K.

What is the market cap of PASG currently?

The market value of PASG currently stands at $14.68M with its latest stock price at $4.57 and 3.21M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	24
Beta	1.42
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PASG Company Profile and Key Details

Passage Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways